Equibles does not estimate personal net worth.
Get an email with a short summary when Phibro Animal Health Corp publishes a filing, an earnings call transcript or a press release.
Get PAHC alertsDonny Bendheim has spoken on 2 earnings calls and 1 other investor event across 1 company, most recently for Phibro Animal Health Corp on August 27, 2026. Phibro Animal Health Corp is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Phibro Animal Health Corp includes Daniel (Dani) Bendheim (CEO), Gerald K. Carlson (CEO and Board Member), Carol A. Wrenn (Chairman) and 7 others.
“Fiscal 2026 was a strong year for Fibro. We delivered record net sales of more than $1.5 billion and increased adjusted EBITDA by 39% to $255 million. In the fourth quarter, sales grew 5% and adjusted EBITDA grew 29%.”
“I'm taking over as CEO beginning July 1. I think historically one of the things about Fibro is we've taken advantage of the safe harbor within animal health as far as not necessarily talking about our pipeline.”
“The first one, which you alluded to, the licensing. We licensed a pharmaceutical product. That will not be anything near-term. It's a long-term play. But the category as a whole, as you see with the Restorist, is something we're very excited about.”
Source not stated
Drug Manufacturers - Specialty & Generic · Healthcare
